文献速递临床试验与 GCP基础与转化研究

BDNF -87甲基化预测重度抑郁患者抗抑郁治疗成功的验证——一项随机评分者盲法试验

Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients-a randomized rater-blinded trial.
PubMed 文献 · Trials · 2024-04-09

该试验为前瞻性随机评分者盲法诊断研究,在德国五所大学医院招募256例重度抑郁障碍患者,随机分为标记组与常规治疗组,评估知晓BDNF基因CpG -87甲基化状态在缓解率上是否非劣于不知晓,同时不良事件是否显著减少。

要点

  • BDNF CpG -87甲基化可能预测单胺类抗抑郁药疗效,本试验旨在验证其预测价值。
  • 主要终点为第49天(±3)HDRS-24评分≤10的缓解率及不良事件发生率。
  • 256例患者随机分入标记组(告知患者及医生甲基化结果)与常规治疗组(不告知)。

核心结论

  • 该试验旨在评估知晓BDNF CpG -87甲基化状态在缓解率上是否非劣于常规治疗,同时是否显著减少不良事件发生率。

研究设计与样本

  • 前瞻性、随机、评分者盲法诊断试验,在德国五所大学医院开展,计划招募256例患者,基线评估于住院时进行,第49天(±3)随访评估,第70天(±3)电话随访。
  • 所有参与者均检测甲基化,并随机分配至标记组或常规治疗组。

主要发现

  • 原文未报告结果。

关键数值与推荐

  • 主要终点包括第49天(±3)达到缓解的患者比例,缓解定义为汉密尔顿抑郁量表24项(HDRS-24)评分≤10,以及不良事件的发生。
  • 标记组中甲基化结果告知患者及其主治医师;常规治疗组中患者及主治医师均不获知标记状态。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brain-derived neurotrophic factor (BDNF) is essential for antidepressant treatment of major depressive disorder (MDD). Our repeated studies suggest that DNA methylation of a specific CpG site in the promoter region of exon IV of the BDNF gene (CpG -87) might be predictive of the efficacy of monoaminergic antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and others. This trial aims to evaluate whether knowing the biomarker is non-inferior to treatment-as-usual (TAU) regarding remission rates while exhibiting significantly fewer adverse events (AE). METHODS: The BDNF trial is a prospective, randomized, rater-blinded diagnostic study conducted at five university hospitals in Germany. The study's main hypothesis is that {1} knowing the methylation status of CpG -87 is non-inferior to not knowing it with respect to the remission rate while it significantly reduces the AE rate in patients experiencing at least one AE. The baseline assessment will occur upon hospitalization and a follow-up assessment on day 49 (± 3). A telephone follow-up will be conducted on day 70 (± 3). A total of 256 patients will be recruited, and methylation will be evaluated in all participants. They will be randomly assigned to either the marker or the TAU group. In the marker group, the methylation results will be shared with both the patient and their treating physician. In the TAU group, neither the patients nor their treating physicians will receive the marker status. The primary endpoints include the rate of patients achieving remission on day 49 (± 3), defined as a score of ≤ 10 on the Hamilton Depression Rating Scale (HDRS-24), and the occurrence of AE. ETHICS AND DISSEMINATION: The trial protocol has received approval from the Institutional Review Boards at the five participating universities. This trial holds significance in generating valuable data on a predictive biomarker for antidepressant treatment in patients with MDD. The findings will be shared with study participants, disseminated through professional society meetings, and published in peer-reviewed journals. TRIAL REGISTRATION: German Clinical Trial Register DRKS00032503. Registered on 17 August 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Maier HB, Neyazi A, Bundies GL, et al. Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients-a randomized rater-blinded trial. Trials. 2024. PMID: 38594753. doi:10.1186/s13063-024-08061-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。